Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Olysio

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Olysio was produced by Janssen.

Remicade safe from biosimilar competition this year, says J&J

Remicade safe from biosimilar competition this year, says J&J

On the downside, hepatitis C therapy Olysio/Sovriad (simeprevir) continued its decline in the face of strong competition in the marketplace from Gilead and AbbVie, falling 86% to just $32m in

2015's 'premium' prices dissuaded J&J from acquisitions, says Gorsky

2015's 'premium' prices dissuaded J&J from acquisitions, says Gorsky to $8.1bn despite heavy competition to hepatitis C therapies Olysio (simeprevir) and Incivo (telaprevir) from Gilead and AbbVie.

J&J's share buyback 'doesn't prevent acquisitions'

J&J's share buyback 'doesn't prevent acquisitions' disease and arthritis drug Remicade (infliximab) and Olysio (simeprevir) for hepatitis C virus offset by growth in newer products. ... Olysio continued its slide in the face of competition from new HCV drugs from Gilead and AbbVie, with sales dropping

Taking a strategic approach

Taking a strategic approach Meanwhile, for Olysio (simeprevir) - one of several new oral drugs that mark a major step forward in hepatitis C treatment - it was an innovative 'pay-if-you-clear' scheme that persuaded

First-ever World Hepatitis Summit calls for national programmes

First-ever World Hepatitis Summit calls for national programmes Drugs such as AbbVie's Exviera (dasabuvir), Johnson &Johnson's Olysio (simprevir), Gilead's Sovaldi (sofosbuvir) and Bristol-Myers Squibb's Daklinza (daclatasvir) have essentially revolutionised treatment, but the latter two

1 2 3 4 5 6 7 8 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics